株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注射型ドラッグデリバリーの世界市場:医療機器のパイプライン評価

Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2018

発行 GlobalData 商品コード 372544
出版日 ページ情報 英文 607 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.58円で換算しております。
Back to Top
注射型ドラッグデリバリーの世界市場:医療機器のパイプライン評価 Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2018
出版日: 2018年04月01日 ページ情報: 英文 607 Pages
概要

当レポートでは、世界の注射型ドラッグデリバリー (薬剤送達) の関連製品の市場における、主要なパイプライン製品とその治験の進行状況について調査すると共に、製品の機能・特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (業績報告・資本取引動向など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 注射型ドラッグデリバリーの概要

第3章 治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:分野別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • パイプライン製品:現在進行中の治験

第4章 治験中のパイプライン製品:企業別

  • 注射型ドラッグデリバリーの企業:治験段階別のパイプライン製品
  • 注射型ドラッグデリバリー:治験段階別のパイプライン製品

第5章 注射型ドラッグデリバリー市場:企業・製品の概要

  • Aciont Inc.
  • Actavis Inc.
  • AdrenaCard, Inc.
  • Allergan, Inc.
  • Alsensa ApS
  • AMAG Pharmaceuticals, Inc.
  • Amgen Inc.
  • Antares Pharma, Inc.
  • Anterion Therapeutics, Inc. (Inactive)
  • Arnali, LLC
  • Artemes Technologies, Inc.
  • AstraZeneca Plc
  • Atanse, Inc.
  • AzureBio, S.L.
  • Becton, Dickinson and Company
  • Bespak Europe Ltd.
  • Biodel Inc.
  • BioMarin Pharmaceutical Inc.
  • BioRestorative Therapies, Inc.
  • Boston University
  • BTG Plc
  • Burke Pharmaceuticals, LLC
  • Callisyn Biomedical Inc
  • Cambridge Consultants Limited
  • Case Western Reserve University
  • Cincinnati Children's Hospital Medical Center
  • Clearside BioMedical, Inc.
  • Consort Medical plc
  • Credence MedSystems, Inc.
  • CrossCoat Medical LLC
  • Cytosial Biomedic, S.a.s.
  • DALI Medical Devices Ltd.
  • Delcath Systems, Inc.
  • DelSite, Inc. (Inactive)
  • Elcam Medical
  • EmboMedics
  • Emergent BioSolutions Inc.
  • Eveon SAS
  • Ghent University
  • Hannover Medical School
  • Indian Institute of Science
  • Inovio Pharmaceuticals, Inc.
  • LyoGo
  • Medicom Innovation Partner a/s
  • Meridian Medical Technologies, Inc.
  • Mertiva AB
  • Microchips Biotech, Inc.
  • Midatech Pharma Plc
  • Milestone Scientific Inc.
  • North Carolina State University
  • Ocelus
  • Oval Medical Technologies Limited
  • Particle Therapeutics Ltd
  • Pfizer Inc.
  • Portal Instruments, Inc.
  • pSivida Corp.
  • Ratio, Inc.
  • Recon Therapeutics, LLC
  • Replenish Inc
  • RepliCel Life Sciences, Inc.
  • RetinaPharma Technologies, Inc.
  • Rx Safes, Inc.
  • Scandinavian Health Ltd
  • Shire Plc
  • Spine Smith, LP
  • Sun Pharmaceutical Industries Limited
  • TCB medical devices
  • Teva Pharmaceutical Industries Ltd.
  • Texas Tech University
  • TheraKine Ltd. (Inactive)
  • Unilife Corporation
  • United Therapeutics Corporation
  • University College London
  • University of Auckland
  • University of Calgary
  • University of California, Irvine
  • University of California, San Diego
  • University of California, San Francisco
  • University of Delaware
  • University of Dundee
  • University of Florida
  • University of Missouri
  • University of Saskatchewan
  • University of Texas at Austin
  • Urodelia SA
  • Vanderbilt University

第6章 注射型ドラッグデリバリー市場:昨今の動向

第7章 付録

図表一覧

目次
Product Code: GDME0528EPD

GlobalData's Medical Devices sector report, "Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Injectable Drug Delivery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Injectable Drug Delivery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Injectable Drug Delivery under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Injectable Drug Delivery and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Injectable Drug Delivery under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 14
  • 1.2 List of Figures 21

2 Introduction 22

  • 2.1 Injectable Drug Delivery Overview 22

3 Products under Development 23

  • 3.1 Injectable Drug Delivery - Pipeline Products by Stage of Development 23
  • 3.2 Injectable Drug Delivery - Pipeline Products by Segment 24
  • 3.3 Injectable Drug Delivery - Pipeline Products by Territory 25
  • 3.4 Injectable Drug Delivery - Pipeline Products by Regulatory Path 26
  • 3.5 Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 27
  • 3.6 Injectable Drug Delivery - Ongoing Clinical Trials 28

4 Injectable Drug Delivery - Pipeline Products under Development by Companies 29

  • 4.1 Injectable Drug Delivery Companies - Pipeline Products by Stage of Development 29
  • 4.2 Injectable Drug Delivery - Pipeline Products by Stage of Development 32

5 Injectable Drug Delivery Companies and Product Overview 35

  • 5.1 3M Co Company Overview 35
  • 5.2 Adamis Pharmaceuticals Corp Company Overview 36
  • 5.3 AdrenaCard, Inc. Company Overview 37
  • 5.4 Allergan Inc Company Overview 38
  • 5.5 Alsensa ApS Company Overview 39
  • 5.6 Antares Pharma Inc Company Overview 40
  • 5.7 Aquavit Pharmaceuticals Inc Company Overview 43
  • 5.8 Artemes Technologies, Inc. Company Overview 44
  • 5.9 Ascendis Pharma A/S Company Overview 45
  • 5.10 Ascil Proyectos SL Company Overview 48
  • 5.11 ASIS Corp Company Overview 49
  • 5.12 AstraZeneca Plc Company Overview 52
  • 5.13 AzureBio SL Company Overview 53
  • 5.14 Becton Dickinson and Co Company Overview 54
  • 5.15 BioCorRx Inc Company Overview 56
  • 5.16 BioMarin Pharmaceutical Inc Company Overview 58
  • 5.17 BioRestorative Therapies Inc Company Overview 59
  • 5.18 Bioxis Pharmaceuticals Company Overview 60
  • 5.19 BTG Plc Company Overview 61
  • 5.20 Burke Pharmaceuticals LLC Company Overview 62
  • 5.21 Callisyn Biomedical Inc Company Overview 63
  • 5.22 Cambridge Consultants Ltd Company Overview 64
  • 5.23 Case Western Reserve University Company Overview 65
  • 5.24 Cincinnati Children's Hospital Medical Center Company Overview 66
  • 5.25 Clearside BioMedical Inc Company Overview 67
  • 5.26 Consort Medical plc Company Overview 71
  • 5.27 DALI Medical Devices Ltd. Company Overview 74
  • 5.28 Delcath Systems Inc Company Overview 77
  • 5.29 DelSite, Inc. (Inactive) Company Overview 80
  • 5.30 Elcam Medical Company Overview 81
  • 5.31 EmboMedics Inc Company Overview 85
  • 5.32 Emergent BioSolutions Inc Company Overview 87
  • 5.33 Eveon SAS Company Overview 90
  • 5.34 FHC Inc Company Overview 92
  • 5.35 GeneSYS-ID Inc Company Overview 93
  • 5.36 Ghent University Company Overview 94
  • 5.37 Inovio Pharmaceuticals Inc Company Overview 95
  • 5.38 InVivo Therapeutics Corp Company Overview 97
  • 5.39 Ipsen SA Company Overview 98
  • 5.40 kaleo Inc Company Overview 99
  • 5.41 LyoGo Company Overview 100
  • 5.42 Meridian Medical Technologies Inc Company Overview 101
  • 5.43 Mertiva AB Company Overview 102
  • 5.44 Milestone Scientific Inc Company Overview 103
  • 5.45 Novo Nordisk AS Company Overview 111
  • 5.46 Novosanis NV Company Overview 112
  • 5.47 Osteo Pharma BV Company Overview 113
  • 5.48 Oval Medical Technologies Ltd Company Overview 114
  • 5.49 Particle Therapeutics Ltd Company Overview 115
  • 5.50 Pfizer Inc Company Overview 116
  • 5.51 Portal Instruments Inc Company Overview 118
  • 5.52 pSivida Corp Company Overview 119
  • 5.53 Queen Elizabeth Hospital Company Overview 127
  • 5.54 QuiO Technologies LLC Company Overview 128
  • 5.55 RepliCel Life Sciences Inc Company Overview 130
  • 5.56 Rescitech Vision Pvt Ltd Company Overview 131
  • 5.57 RetinaPharma Technologies Inc Company Overview 132
  • 5.58 Roche Diagnostics International Ltd Company Overview 133
  • 5.59 Scandinavian Health Ltd Company Overview 136
  • 5.60 Sun Pharma Advanced Research Company Ltd Company Overview 137
  • 5.61 TCB medical devices Company Overview 138
  • 5.62 Terumo Corp Company Overview 139
  • 5.63 Teva Pharmaceutical Industries Ltd Company Overview 141
  • 5.64 TheraKine Inc (Inactive) Company Overview 143
  • 5.65 Twin Star Medical Inc Company Overview 144
  • 5.66 Unilife Corporation Company Overview 145
  • 5.67 University of Calgary Company Overview 148
  • 5.68 University of California San Diego Company Overview 149
  • 5.69 University of California San Francisco Company Overview 151
  • 5.70 University of Delaware Company Overview 152
  • 5.71 University of Dundee Company Overview 153
  • 5.72 University of Florida Company Overview 154
  • 5.73 University of Saskatchewan Company Overview 156
  • 5.74 University of Texas at Austin Company Overview 157
  • 5.75 Vanderbilt University Company Overview 158
  • 5.76 West Pharmaceutical Services Inc Company Overview 159
  • 5.77 Windgap Medical Inc Company Overview 160
  • 5.78 XERIS Pharmaceuticals Inc Company Overview 161
  • 5.79 Ypsomed Holding AG Company Overview 162

6 Injectable Drug Delivery- Recent Developments 163

  • 6.1 Mar 08, 2018: Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and Immunology 163
  • 6.2 Mar 06, 2018: Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Joint Congress With the World Allergy Organization 163
  • 6.3 Mar 06, 2018: Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director 164
  • 6.4 Mar 06, 2018: Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government & Public Affairs 164
  • 6.5 Mar 05, 2018: Pfizer Names Dan R. Littman As Board Director 165
  • 6.6 Mar 02, 2018: FDA to Review DUPIXENT (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma 165
  • 6.7 Mar 02, 2018: Clearside Biomedical Schedules Conference Call to Review Topline Results from Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis 166
  • 6.8 Mar 01, 2018: Alkermes Names James Robinson as President and Chief Operating Officer 167
  • 6.9 Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 167
  • 6.10 Feb 28, 2018: Catalent Completes $4.6 Million Expansion at Singapore Facility 169
  • 6.11 Feb 27, 2018: Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta (pegfilgrastim) 169
  • 6.12 Feb 26, 2018: West Names Silji Abraham Chief Digital And Transformation Officer 170
  • 6.13 Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 171
  • 6.14 Feb 26, 2018: Recipharm: Chief Financial Officer to leave Recipharm 172
  • 6.15 Feb 25, 2018: Dr. Reddy's Laboratories Provides Update on USFDA Audit of its API Manufacturing Plant at Srikakulam, India 172
  • 6.16 Feb 23, 2018: Pfizer Appoints Albert Bourla As Board Director 172
  • 6.17 Feb 22, 2018: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results 172
  • 6.18 Feb 22, 2018: BioMarin Reports Fourth Quarter 2017 Financial Results 176
  • 6.19 Feb 22, 2018: Recipharm Reports Fourth Quarter And Full Year 2017 179
  • 6.20 Feb 21, 2018: United Therapeutics Reports 2017 Fourth Quarter And Annual Financial Results 180
  • 6.21 Feb 21, 2018: Merck Invests Additional €40 Million to Enhance Manufacturing and Distribution in Asia 182
  • 6.22 Feb 20, 2018: Halozyme Reports Fourth Quarter And Full-Year 2017 Results 183
  • 6.23 Feb 20, 2018: Catalent Announces Changes to its Board of Directors 184
  • 6.24 Feb 19, 2018: Dr Reddy's Laboratories: Update on US Lawsuit 185
  • 6.25 Feb 15, 2018: West Announces Fourth-Quarter and Full-Year 2017 Results and Announces Quarterly Dividend 185
  • 6.26 Feb 14, 2018: Antares Pharma Announces FDA Approval of Partners Product Utilizing Our QuickShot Auto Injector 187
  • 6.27 Feb 14, 2018: Alkermes Names Shane Cooke As Board Director 188
  • 6.28 Feb 14, 2018: Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017 188
  • 6.29 Feb 14, 2018: Recipharm Appoints President Development Services to Drive End to End Offering 190
  • 6.30 Feb 14, 2018: Alkermes Reports Q4 2017 Financial Results 191
  • 6.31 Feb 12, 2018: BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102 193
  • 6.32 Feb 08, 2018: First targeted treatment for adults with moderate-to-severe atopic dermatitis, Dupixent, now available in Canada 194
  • 6.33 Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results 195
  • 6.34 Feb 07, 2018: SelfDose Patient-Controlled Injector Named as Recipient of Pharmapack Exhibitor Innovation Award 203
  • 6.35 Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance 204
  • 6.36 Feb 07, 2018: pSivida Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines 206
  • 6.37 Feb 06, 2018: BD Announces Results For 2018 First Fiscal Quarter; Provides Fiscal 2018 Guidance Updated For Inclusion Of Bard 207
  • 6.38 Feb 06, 2018: Covestro plastic enables medical device innovation 208
  • 6.39 Feb 06, 2018: MRI Interventions Announces Record 629 ClearPoint Cases in 2017 209
  • 6.40 Feb 06, 2018: Teva Pharmaceuticals laid off 46 employees in Parsippany 210
  • 6.41 Feb 05, 2018: Catalent Reports Second Quarter Fiscal 2018 Financial Results 210
  • 6.42 Feb 02, 2018: Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe 214
  • 6.43 Feb 02, 2018: AstraZeneca: Full-Year 2017 Results 214
  • 6.44 Feb 02, 2018: Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results 216
  • 6.45 Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies) 221

7 Appendix 602

  • 7.1 Methodology 602
  • 7.2 About GlobalData 605
  • 7.3 Contact Us 605
  • 7.4 Disclaimer 605

List of Tables

1.1 List of Tables

  • Table 1: Injectable Drug Delivery - Pipeline Products by Stage of Development 24
  • Table 2: Injectable Drug Delivery - Pipeline Products by Segment 25
  • Table 3: Injectable Drug Delivery - Pipeline Products by Territory 26
  • Table 4: Injectable Drug Delivery - Pipeline Products by Regulatory Path 27
  • Table 5: Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 28
  • Table 6: Injectable Drug Delivery - Ongoing Clinical Trials 29
  • Table 7: Injectable Drug Delivery Companies - Pipeline Products by Stage of Development 30
  • Table 8: Injectable Drug Delivery - Pipeline Products by Stage of Development 33
  • Table 9: 3M Co Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 10: 3M Hollow Microstructured Transdermal System - Product Status 36
  • Table 11: 3M Hollow Microstructured Transdermal System - Product Description 36
  • Table 12: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 13: Symjepi - Junior Version - Product Status 37
  • Table 14: Symjepi - Junior Version - Product Description 37
  • Table 15: AdrenaCard, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 16: Adrenacard Auto-Injector - Product Status 38
  • Table 17: Adrenacard Auto-Injector - Product Description 38
  • Table 18: Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 19: NOVADUR Intravitreal Implant - Product Status 39
  • Table 20: NOVADUR Intravitreal Implant - Product Description 39
  • Table 21: Alsensa ApS Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 22: SQJCT - Product Status 40
  • Table 23: SQJCT - Product Description 40
  • Table 24: Antares Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 25: QuickShot Testosterone (QST) - Product Status 41
  • Table 26: QuickShot Testosterone (QST) - Product Description 41
  • Table 27: Teva Pen 1 - Product Status 42
  • Table 28: Teva Pen 1 - Product Description 42
  • Table 29: Vibex EPI - Product Status 42
  • Table 30: Vibex EPI - Product Description 42
  • Table 31: Vibex QS M - Product Status 43
  • Table 32: Vibex QS M - Product Description 43
  • Table 33: Aquavit Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 34: PITO-001 - Product Status 44
  • Table 35: PITO-001 - Product Description 44
  • Table 36: Artemes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 37: Artemes Magnetic Injection System - Product Status 45
  • Table 38: Artemes Magnetic Injection System - Product Description 45
  • Table 39: Ascendis Pharma A/S Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 40: TransCon hGH Auto-Injector - Product Status 46
  • Table 41: TransCon hGH Auto-Injector - Product Description 46
  • Table 42: Ascendis Pharma A/S - Ongoing Clinical Trials Overview 47
  • Table 43: TransCon hGH Auto-Injector - A Multicenter, Phase III, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children with Growth Hormone Deficiency (GHD) 48
  • Table 44: Ascil Proyectos SL Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 45: Prefilled Device - Product Status 49
  • Table 46: Prefilled Device - Product Description 49
  • Table 47: ASIS Corp Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 48: Automatic Subdermal Injection System - Product Status 50
  • Table 49: Automatic Subdermal Injection System - Product Description 50
  • Table 50: ASIS Corp - Ongoing Clinical Trials Overview 51
  • Table 51: Automatic Subdermal Injection System - ASIS for Botox in Chronic Migraine 52
  • Table 52: Automatic Subdermal Injection System - ASIS for Botox in Upper Limb Spasticity 52
  • Table 53: Automatic Subdermal Injection System - ASIS for Enbrel in Plaque Psoriasis 52
  • Table 54: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 55: Bydureon BCise Autoinjector Device - Product Status 53
  • Table 56: Bydureon BCise Autoinjector Device - Product Description 53
  • Table 57: AzureBio SL Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 58: Injectable Needle - Product Status 54
  • Table 59: Injectable Needle - Product Description 54
  • Table 60: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 61: BD Intevia Disposable Autoinjector - Product Status 55
  • Table 62: BD Intevia Disposable Autoinjector - Product Description 55
  • Table 63: BD Libertas Wearable Injector - Product Status 56
  • Table 64: BD Libertas Wearable Injector - Product Description 56
  • Table 65: T2 Patch Wearable Injector - Product Status 56
  • Table 66: T2 Patch Wearable Injector - Product Description 56
  • Table 67: BioCorRx Inc Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 68: Injectable Naltrexone Implant - BICX101 - Product Status 57
  • Table 69: Injectable Naltrexone Implant - BICX101 - Product Description 57
  • Table 70: Naltrexone Implant - BICX102 - Product Status 58
  • Table 71: Naltrexone Implant - BICX102 - Product Description 58
  • Table 72: BioMarin Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 73: Pegvaliase Pre-filled Syringe - Product Status 59
  • Table 74: Pegvaliase Pre-filled Syringe - Product Description 59
  • Table 75: BioRestorative Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 76: Curved Needle Device - Product Status 60
  • Table 77: Curved Needle Device - Product Description 60
  • Table 78: Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 79: Vaccine Delivery Device - Product Status 61
  • Table 80: Vaccine Delivery Device - Product Description 61
  • Table 81: BTG Plc Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 82: Varithena - Aesthetic Leg Veins - Product Status 62
  • Table 83: Varithena - Aesthetic Leg Veins - Product Description 62
  • Table 84: Burke Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 85: BURKE201 Needle Injection Pen - Product Status 63
  • Table 86: BURKE201 Needle Injection Pen - Product Description 63
  • Table 87: Callisyn Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 88: TACEspheres Drug Eluting Embolic Microspheres - Product Status 64
  • Table 89: TACEspheres Drug Eluting Embolic Microspheres - Product Description 64
  • Table 90: Cambridge Consultants Ltd Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 91: Flexi-ject - Product Status 65
  • Table 92: Flexi-ject - Product Description 65
  • Table 93: Case Western Reserve University Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 94: Pressure Driven Local Drug Delivery System - Liver Cancer - Product Status 66
  • Table 95: Pressure Driven Local Drug Delivery System - Liver Cancer - Product Description 66
  • Table 96: Cincinnati Children's Hospital Medical Center Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 97: Pre-Filled Syringe With Flush - Product Status 67
  • Table 98: Pre-Filled Syringe With Flush - Product Description 67
  • Table 99: Clearside BioMedical Inc Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 100: SCS Microinjector - Product Status 68
  • Table 101: SCS Microinjector - Product Description 68
  • Table 102: Clearside BioMedical Inc - Ongoing Clinical Trials Overview 69
  • Table 103: SCS Microinjector - A Phase III, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema Associated with Non-infectious Uveitis 70

List of Figures

1.2 List of Figures

  • Figure 1: Injectable Drug Delivery - Pipeline Products by Stage of Development 24
  • Figure 2: Injectable Drug Delivery - Pipeline Products by Segment 25
  • Figure 3: Injectable Drug Delivery - Pipeline Products by Territory 26
  • Figure 4: Injectable Drug Delivery - Pipeline Products by Regulatory Path 27
  • Figure 5: Injectable Drug Delivery - Pipeline Products by Estimated Approval Date 28
  • Figure 6: Injectable Drug Delivery - Ongoing Clinical Trials 29
Back to Top